M Ávila-Núñez, O Lima, A Sousa, M Represa, P Rubiñán, P Celestino, M Garrido-Ventín, L García-Formoso, F Vasallo-Vidal, L Martinez-Lamas, A Pérez-Landeiro, M Rubianes, M T Pérez-Rodríguez
INTRODUCTION: Carbapenems (CR) have traditionally been the first line treatment for bacteremia caused by AmpC-producing Enterobacterales. However, CR have a high ecological impact, and carbapenem-resistant strains continue rising. Thus, other treatment alternatives like Piperacillin-Tazobactam (P-T) or Cefepime (CEF) and oral sequential therapy (OST) are being evaluated. METHODS: We conducted a retrospective, single-centre observational study. All adult patients with AmpC-producing Enterobacterales bacteremia were included...
August 17, 2023: Annals of Clinical Microbiology and Antimicrobials